For the Inventor, By the Inventor

Enter assignee name

Richmond, CA, United States of America

Sangamo Biosciences, Inc.

USPTO Granted Patents = 160

CIPO Patents = 15

EPO Patents = 43

Trademarks = 2

Forward Citations = 8,388

Loading Chart...

Loading Chart...

97 inventors (with patents filed for the assignee):

Fyodor Urnov (47 out of 80 patents)

Edward J Rebar (43 out of 88 patents)

Philip D Gregory (38 out of 62 patents)

4. Jeffrey C Miller (37 out of 86 patents)

5. Michael C Holmes (34 out of 64 patents)

6. Casey Christopher Case (26 out of 40 patents)

7. Andrew Jamieson (24 out of 26 patents)

8. Stephen P Eisenberg (20 out of 30 patents)

9. Lei Zhang (20 out of 43 patents)

10. David Paschon (19 out of 49 patents)

11. Trevor Collingwood (16 out of 20 patents)

12. Alan P Wolffe (15 out of 16 patents)

13. Eric E Jarvis (14 out of 28 patents)

14. Qiang Liu (13 out of 16 patents)

15. George N Cox (13 out of 58 patents)

Core Competencies:

Zinc Finger Proteins

Gene Correction

Targeted Integration

Stem Cell Modulation

T Cell Modifying Compounds

Huntington's Disease Treatment

Viral Entry Inhibition

Genomic Modification

DNA-Binding Proteins

Hemophilia B Treatment

Transgene Expression Regulation

Engineered Nucleases

160 patents: Sort by Forward Citations

1. 11884930 - Method of inactivating a glucocorticoid receptor gene in an isolated cell (2024-01-30),

2. 9650648 - Methods and compositions for treatment of a genetic condition (2017-05-16),

3. 9631201 - Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis (2017-04-25),

4. 9631187 - Methods and compositions for gene correction (2017-04-25),

5. 9631186 - Methods and compositions for targeted single-stranded cleavage and targeted integration (2017-04-25),

6. 9629930 - Methods and compositions for treating hemophilia B (2017-04-25),

7. 9624509 - Modulation of stem cells using zinc finger proteins (2017-04-18),

8. 9624498 - Methods and compositions for regulation of zinc finger protein expression (2017-04-18),

9. 9616090 - Gene correction of SCID-related genes in hematopoietic stem and progenitor cells (2017-04-11),

10. 9597357 - T cell modifying compounds and uses thereof (2017-03-21),

11. 9574211 - Methods and compositions for prevention or treatment of a disease (2017-02-21),

12. 9567609 - Compositions for linking DNA-binding domains and cleavage domains (2017-02-14),

13. 9567573 - [object Object] (2017-02-14),

14. 9566352 - Methods and compositions for inhibiting viral entry into cells (2017-02-14),

15. 9523098 - Targeted modification of malate dehydrogenase (2016-12-20),

Sangamo Biosciences, Inc. is a clinical-stage biotechnology company focused on developing genomic medicines to treat patients with genomic diseases. With advanced technologies like gene therapy and gene editing, Sangamo aims to provide novel solutions for genetic disorders, cancer, and other diseases. The company’s research and development efforts are primarily focused on three areas: gene therapy, ex vivo cell therapy, and in vivo genome editing. By leveraging its proprietary platform, Sangamo Biosciences strives to revolutionize the treatment of various genetic conditions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

160 Patents

#2 in Richmond, CA

#546 in California

#2,396 in US

#5,009 in the World

Richmond, CA, United States of America

Sangamo Biosciences, Inc.

Forward Citations = 8,388

97 inventors:

Fyodor Urnov (47 out of 80 patents)

Edward J Rebar (43 out of 88 patents)

Philip D Gregory (38 out of 62 patents)

4. Jeffrey C Miller (37 out of 86 patents)

5. Michael C Holmes (34 out of 64 patents)

Please report any incorrect information to support@idiyas.com

Loading…